Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03410043 · ClinicalTrials.gov registry record · Phase 2

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

A Phase 2 study of Stage IV Lung Cancer AJCC v8 and Lung Non-Small Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
173
Enrollment target
4
Study locations

NCT03410043 is a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 173 participants, above the 96-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (80% higher). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03410043, a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
173 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving osimertinib, surgery, and radiation therapy may work better at treating non-small cell lung cancer with EGFR mutations.

Interventions

  • DRUG Osimertinib
  • RADIATION Radiation Therapy
  • PROCEDURE Therapeutic Conventional Surgery

Study Locations (4)

California

  • UCSF Medical Center-Mount Zion - San Francisco

Colorado

  • University of Colorado - Denver

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2018-01-17
Est. Completion 2026-04-01
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT03410043

The ClinicalTrials.gov registry entry for NCT03410043 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 96-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (80% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Osimertinib is the first listed.

NCT03410043 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, New York.

Frequently Asked Questions

What is clinical trial NCT03410043 about?

NCT03410043 is a clinical study titled "Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study". This phase II trial studies how well osimertinib, surgery, and radiation therapy work in treating patients with stage IIIB or IV non-small cell lung cancer with EGFR mutations. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy us...

What is the current status of trial NCT03410043?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2018-01-17. Estimated completion is 2026-04-01.

What conditions does trial NCT03410043 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8.

What interventions are being tested in trial NCT03410043?

The interventions under investigation include: Osimertinib (DRUG), Radiation Therapy (RADIATION), Therapeutic Conventional Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT03410043?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03410043 being conducted?

This trial has 4 study locations across California, Colorado, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.